Name | Value |
---|---|
Revenues | 55.1M |
Cost of Revenue | 6.5M |
Gross Profit | 48.6M |
Operating Expense | 279.2M |
Operating I/L | -230.6M |
Other Income/Expense | 300.7M |
Interest Income | 72.1M |
Pretax | 70.1M |
Income Tax Expense | 12.7M |
Net Income/Loss | 95.3M |
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company specializing in the research and development of medicines for various therapeutic areas. The company's product candidates target solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. By developing these innovative treatments, Roivant Sciences generates revenue through the commercialization and sale of its pharmaceutical products, addressing unmet medical needs and improving patient outcomes across a wide range of conditions.